Emerging Biomarkers for Early Detection and Prognosis of Bile Duct Cancer
One of the key aspects of precision medicine in bile duct cancer is the identification of genetic mutations and alterations that drive tumor growth. Advances in genomic sequencing technologies have made it possible to identify specific mutations in the DNA of cancer cells with great precision. For example, mutations in genes such as IDH1, IDH2, FGFR2, and BRAF have been found in subsets of bile duct cancer patients. These mutations can serve as targets for personalized therapies.
Targeted therapies for Bile Duct Cancer can take different forms. Small molecule inhibitors, such as those targeting the FGFR2 gene, can be used to block specific signaling pathways that promote tumor growth. Monoclonal antibodies, on the other hand, can be designed to recognize and bind to specific proteins on the surface of cancer cells, inhibiting their growth or facilitating immune-mediated destruction of the tumor. These targeted therapies offer a more precise and effective approach compared to traditional chemotherapy, which often has limited efficacy and can cause significant side effects.
Read more @ http://sparkblog45.weebly.com/article/bile-duct-cancer-carry-the-digestive-fluid-bile
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian